News

The company is seeking approval of the fixed-dose combination (FDC) tablet for use in combination with other antiretroviral agents to treat patients with HIV-1. Developed by Gilead Sciences,

The previous clinical trials have showed that the new therapeutic option for the standard therapy of patients with hormone-resistant tumors reduces the risk of death by about 35%.

The Phase III research study was double blind, randomized, and placebo-controlled study designed to assess the efficacy of Dysport.. The study, which enrolled 243 patients, was conducted in

With the acquisition, Bio-Rad will expand its Digital Biology Center as well as establish a research and development site in Cambridge, Massachusetts. GnuBIO has developed a DNA sequencing

ThioBridge was developed by PolyTherics for site-specific conjugation of cytotoxic payloads to antibodies to provide more stable and less heterogeneous ADCs. MacroGenics has two antibody technology platforms, which

These data will be presented at the 29th Annual European Association of Urology (EAU) Congress taking place from 11 April to 15 April 2014 in Stockholm, Sweden. Dendreon

Results from the SAPPHIRE-II study were presented at the congress on 10 April 2014. Additionally, results from both the SAPPHIRE-I and SAPPHIRE-II studies have been published on-line in

This product is the generic version of FROVA®, which is used to treat acute migraine headaches in adults. As a result of the decision, the Court has vacated

This is in addition to the South Okanagan producing facility currently under evaluation. The parties have agreed to an exclusive 45-day negotiating period. There is no guarantee that